Results 141 to 150 of about 31,287 (200)
One cell at a time: HbF distribution in sickle cell disease. [PDF]
Blood AdvKhandros E, Steinberg MH.
europepmc +1 more source
Persistent thrombocytosis in β-thalassemia post-splenectomy: A STROBE-compliant retrospective cohort study at a Jordanian referral center. [PDF]
Medicine (Baltimore)Alesufi A +9 more
europepmc +1 more source
Case Report: Chronic myeloid leukemia in a 13-year-old-a rare pediatric case of extreme hyperleukocytosis in chronic phase. [PDF]
Front Med (Lausanne)Asees M, Abdalhaq T, Amer J.
europepmc +1 more source
Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease. [PDF]
Br J HaematolZhang X +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Archives of Dermatology, 1970
In a double-blind study, nine of ten cases of severe psoriasis demonstrated clinical and histopathologic response to hydroxyurea. No toxic reactions were noted. The drug may be less toxic than methotrexate and is efficacious in the management of psoriasis.
Robert B. Livingston, Stephen K. Carter
openaire +2 more sources
In a double-blind study, nine of ten cases of severe psoriasis demonstrated clinical and histopathologic response to hydroxyurea. No toxic reactions were noted. The drug may be less toxic than methotrexate and is efficacious in the management of psoriasis.
Robert B. Livingston, Stephen K. Carter
openaire +2 more sources
British Journal of Dermatology, 2006
SUMMARY Nine patients who were treated for psoriasis with hydroxyurea displayed peripheral macrocytosis. Mild megaloblastic changes were also seen in the bone marrow of three patients. One patient receiving hydroxyurea developed mild anaemia, another leukopenia. Macrocytosis did not appear to be secondary to an alteration in serum B12 or folate levels.
S, Spier +3 more
openaire +3 more sources
SUMMARY Nine patients who were treated for psoriasis with hydroxyurea displayed peripheral macrocytosis. Mild megaloblastic changes were also seen in the bone marrow of three patients. One patient receiving hydroxyurea developed mild anaemia, another leukopenia. Macrocytosis did not appear to be secondary to an alteration in serum B12 or folate levels.
S, Spier +3 more
openaire +3 more sources
Journal of the American Academy of Dermatology, 1991
Hydroxyurea's place in the scheme of psoriasis therapy has diminished in recent years. Some practitioners mistakenly believe that it is used only in desperate situations, is of little or no benefit in patients unresponsive to more conventional systemic therapies, and may predispose patients to the development of secondary malignancies.
A S, Boyd, K H, Neldner
openaire +2 more sources
Hydroxyurea's place in the scheme of psoriasis therapy has diminished in recent years. Some practitioners mistakenly believe that it is used only in desperate situations, is of little or no benefit in patients unresponsive to more conventional systemic therapies, and may predispose patients to the development of secondary malignancies.
A S, Boyd, K H, Neldner
openaire +2 more sources
Mutation Research/Reviews in Genetic Toxicology, 1975
Hydroxyurea (HU) is an anti-leukaemia and anti-tumour drug which has also found limited application in the treatment of dermatological disorders. It is a potent inhibitor of DNA synthesis in many organisms from viruses to man and in cell culture systems. To a lesser degree it can also inhibit RNA and protein synthesis.
openaire +2 more sources
Hydroxyurea (HU) is an anti-leukaemia and anti-tumour drug which has also found limited application in the treatment of dermatological disorders. It is a potent inhibitor of DNA synthesis in many organisms from viruses to man and in cell culture systems. To a lesser degree it can also inhibit RNA and protein synthesis.
openaire +2 more sources